Business
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical OfficerPHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith w
About this update from Context Therapeutics Inc.
[{"type":"image","alt":"Context Therapeutics Inc.","displaySize":"","headline":null,"caption":"Context Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YbSmZ9VBJ1k54h3C06aWkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85","width":300,"height":140}},"lazy":false},{"type":"text","content":"Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer","length":70,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith will continue in a dual capacity as interim CMO and a member of the Company’s Board of Directors (“Board”) while the Company conducts a search for a new, full-time CMO. Dr. Smith will take over key responsibilities on an interim basis, ensuring continuity in strategic guidance for the Company’s clinical development programs.","length":755,"tagName":"p"},{"type":"text","content":"Dr. Smith has served on Context’s Board since 2024 and is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She was previously Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals and has also held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb.","length":397,"tagName":"p"},{"type":"text","content":"“As we take the next steps in advancing our pipeline, I am delighted to have Karen’s support and leadership. Karen’s experience in drug development will make her guidance invaluable through this transition,” said Martin Lehr, CEO of Context. “I am grateful to Claudio for his contributions to Context.”","length":302,"tagName":"p"},{"type":"text","content":"About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a bio...